Conventional chemotherapy remains limited by incorrect targeting and excessive toxicity to the entire organism and clinical evidence suggests that not one in every 10 anticancer agents gets to the tumour site but the remainder of the concentration is incorporated in normal tissue. These limitations reduce the effectiveness of therapy and increase the risk of serious side effects, particularly in deep-rooted in-depth cancers. The paper discusses AI-based robotic targeted drug delivery technology capable of improving cancer treatment through smart localisation, controlled motion, and adaptive drug delivery.A qualitative thematic analysis approach was used to examine the latest developments in the field of artificial intelligence, medical robotics, and delivery systems based on nanotechnology. The pertinent research in the field of engineering, oncology and intelligent healthcare systems was reviewed to determine the main technological themes that influence the accuracy, safety and clinical feasibility of treatment. The talk focused on the integration of the tumour sensing algorithms, carrier robotic arms, controlled release mechanisms and real-time monitoring in a closed-loop therapeutic framework.The findings indicate that AI, robotics, and nano-scale delivery could increase the accuracy of localisation by more than 25 times compared to the conventional delivery and reduce off-target drug delivery. However, reliability, regulation and cost issues are also present due to the greater complexity of the system.This research has merits as it suggests a system architecture of the intelligent drug delivery and the need to conduct future studies to determine the safety validation, energy-efficient computation, and clinically scalable robots to enable the feasibility of practical application in precise oncology.